- Home
- APLS vs CENX Comparison
APLS vs CENX Comparison
Compare APLS & CENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APLS | CENX |
|---|---|---|
| Founded | 2009 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aluminum |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 6.1B |
| IPO Year | 2015 | 2004 |
Fundamental Metrics
Financial Performance| Metric | APLS | CENX |
|---|---|---|
| Price | $41.05 | $66.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 21 | 3 |
| Target Price | $33.59 | ★ $65.67 |
| AVG Volume (30 Days) | ★ 8.3M | 1.4M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.50 | N/A |
| EPS | 0.15 | ★ 3.23 |
| Revenue | $1,003,782,000.00 | ★ $1,893,200,000.00 |
| Revenue This Year | N/A | $20.77 |
| Revenue Next Year | $18.19 | $14.58 |
| P/E Ratio | $273.60 | ★ $20.03 |
| Revenue Growth | ★ 28.46 | N/A |
| 52 Week Low | $16.61 | $15.13 |
| 52 Week High | $41.14 | $68.69 |
Technical Indicators
Market Signals| Indicator | APLS | CENX |
|---|---|---|
| Relative Strength Index (RSI) | 84.57 | 61.69 |
| Support Level | $19.29 | $45.49 |
| Resistance Level | $41.14 | $67.02 |
| Average True Range (ATR) | 0.06 | 3.96 |
| MACD | -0.65 | 0.48 |
| Stochastic Oscillator | 58.33 | 93.48 |
Price Performance
Historical ComparisonAbout APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
About CENX Century Aluminum Company
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. The company also owns a carbon anode production facility in the Netherlands.